Indatuximab ravtansine
Based on 1 publication(s) in Google Scholar
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities.
For research use only. We do not sell to patients.
- Purity: 95.78%
- CAS No.: 1238517-16-2
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Indatuximab ravtansine
More
Biological Activity
Indatuximab ravtansine (1 pM-100 nM; 5 days) shows cytotoxic effects in RPMI 8226, MOLP-8 and U266 cell lines (significant CD138 expression), with IC50 values of 200 pM, 40 pM, and 20 pM for RPMI 8226, MOLP-8, and U266 cells, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RPMI 8226, MOLP-8 and U266 cell lines
-
Concentration:1 pM-100 nM
-
Incubation Time:5 days
-
Result:Showed cytotoxic effects in RPMI 8226, MOLP-8 and U266 cell lines.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID mice inoculated with MOLP-8 multiple myeloma xenografts[1]
-
Dosage:5.3 mg/kg, 10.6 mg/kg or 21.2 mg/kg
-
Administration:i.v.; once
-
Result:Inhibited multiple myeloma tumour growth in vivo and improved host survival.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1238517-16-2
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Indatuximab ravtansine]
-
Synonyms
BT-062; nBT062-DM4
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Indatuximab ravtansine Related Classifications
HY-141607 Related Classifications
Powered by Bioz